Ischemic Postconditioning in STEMI Patients Treated With Primary PCI
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorRigshospitalet, Denmark
About this trial
In a prospective, randomized clinical trial the iPOST2 trial will determine whether ischemic postconditioning reduces reperfusion injury and this will translate into improved clinical outcome of heart failure and death for STEMI patients who present with TIMI0-1 undergoing primary PCI
Eligibility criteria
Qualifiers
Age ≥18 years
Acute onset of chest pain with < 12 hours duration
STEMI as characterized by 2 mm ST elevation in 2 or more V1 through V4 leads or presumed new left bundle branch block with minimum of 1 mm concordant ST elevation or 1 mV ST-segment elevation in the limb lead (II, III and aVF, I, aVL) and V4-V6 or ST depression in 2 or more V1 through V4 leads indicating posterior AMI.
TIMI flow 0-1 in infarct related artery
Disqualifiers
Potential pregnancy
Refusal to participate
OHCA without subsequent consciousness despite ROSC
Thrombectomy considered unavoidable
Trial design
Treatments tested in this trial
- Ischemic postconditioning
- Conventional
Treatment groups
1,800 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov